Tezampanel
CAS: 154652-83-2
Ref. 3D-EGA65283
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Informação sobre produto
- (3S,4aR,6R,8aR)-Decahydro-6-[2-(2H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid
- 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S,4aR,6R,8aR)-
- 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-
- 3-Isoquinolinecarboxylic acid, decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-, [3S-(3α,4aα,6β,8aα)]-
- 3-Isoquinolinecarboxylic acid, decahydro-6-[2-(2H-tetrazol-5-yl)ethyl]-, (3S,4aR,6R,8aR)-
- 6-(2-(1H-Tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
- Decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-3-isoquinolinecarboxylic acid
- Ly 293558
- Ngx 424
- TED-isoquinoline-3-COOH
- Ver mais sinónimos
- Tezampanel (anhydrous)
- Unii-Ga36S2O9C2
Tezampanel is a prodrug that is converted to casopitant mesylate after oral administration. Casopitant mesylate is an experimental drug that acts as a selective antagonist at the NK1 receptor, which is involved in mediating pain and inflammation. Tezampanel has been shown to have antinociceptive properties in animal studies. It also reversibly inhibits the activity of glutamate receptors, including NMDA receptors, which are involved in the development of migraine headaches. Clinical studies have demonstrated that tezampanel may be effective for the treatment of migraine headaches.
Propriedades químicas
Consulta técnica sobre: 3D-EGA65283 Tezampanel
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.